Hyper-IgM syndrome type 3

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Hyper-IgM syndrome type 3 | |
|---|---|
| Synonyms | CD40 deficiency |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Recurrent infections, neutropenia, autoimmune disorders |
| Complications | Liver disease, cancer |
| Onset | Infancy |
| Duration | Chronic |
| Types | N/A |
| Causes | Genetic mutation in the CD40 gene |
| Risks | Family history of the condition |
| Diagnosis | Genetic testing, immunoglobulin level measurement |
| Differential diagnosis | Other types of Hyper-IgM syndrome, Common variable immunodeficiency |
| Prevention | Genetic counseling |
| Treatment | Immunoglobulin replacement therapy, hematopoietic stem cell transplantation |
| Medication | Antibiotics for infections, immunosuppressants |
| Prognosis | Variable, depending on treatment and complications |
| Frequency | Rare |
| Deaths | N/A |

Hyper-IgM syndrome type 3 is a rare immunodeficiency disorder characterized by a defective immune system that primarily affects males. The condition is caused by mutations in the CD40 ligand gene, which is involved in the activation of B cells and their subsequent transformation into plasma cells that produce antibodies.
Symptoms[edit]
The symptoms of Hyper-IgM syndrome type 3 typically begin in infancy or early childhood. They include frequent and severe bacterial infections, pneumonia, sinusitis, and meningitis. Other symptoms may include diarrhea, skin rashes, and liver disease.
Causes[edit]
Hyper-IgM syndrome type 3 is caused by mutations in the CD40 ligand gene. This gene provides instructions for making a protein that is essential for the activation of B cells, which are a type of white blood cell that produces antibodies. When the CD40 ligand protein is defective, B cells cannot transform into plasma cells to produce antibodies, leading to an impaired immune response.
Diagnosis[edit]
The diagnosis of Hyper-IgM syndrome type 3 is based on the presence of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and specialized tests. These tests may include measuring the levels of different types of antibodies in the blood and genetic testing to identify mutations in the CD40 ligand gene.
Treatment[edit]
There is currently no cure for Hyper-IgM syndrome type 3. Treatment is aimed at managing symptoms and preventing infections. This may include antibiotics to treat bacterial infections, immunoglobulin therapy to boost the immune system, and in severe cases, a bone marrow transplant.
Prognosis[edit]
The prognosis for individuals with Hyper-IgM syndrome type 3 varies. Some individuals have a normal lifespan with proper management, while others may have a shortened lifespan due to severe recurrent infections and complications such as liver disease.
See also[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian